ArticleInfection and immunity2001
Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection.
Article in Infection and immunity, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 103 citations in OpenAlex.
- Rationally designed minimized TbpB confers broad protection against meningococcal infection.PLoS pathogens · 2026Article
- Structural insights into the mechanism underpinning iron piracy in pathogenicScience advances · 2026Article
- Surface protein machineries in Gram-negative bacteria.Journal of cell science · 2025Review
- Immunoprotective effects of extracellular products ofFrontiers in microbiology · 2025Article
- Reverse vaccinology-based identification of a novel surface lipoprotein that is an effective vaccine antigen against bovine infections caused by Pasteurella multocida.PLoS pathogens · 2023Article
- Point Mutations in TbpA Abrogate Human Transferrin Binding in Neisseria gonorrhoeae.Infection and immunity · 2022Article
- Targeting bacterial transferrin and lactoferrin receptors for vaccines.Trends in microbiology · 2022Review
- Article
- Application of TonB-Dependent Transporters in Vaccine Development of Gram-Negative Bacteria.Frontiers in cellular and infection microbiology · 2020Review
- Utility of Hybrid Transferrin Binding Protein Antigens for Protection Against Pathogenic Neisseria Species.Frontiers in immunology · 2019Article
- Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice FromFrontiers in immunology · 2019Article
- Virulence factors of Moraxella catarrhalis outer membrane vesicles are major targets for cross-reactive antibodies and have adapted during evolution.Scientific reports · 2018Article
- Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against Neisseria meningitidis Serogroup B in England.Clinical and vaccine immunology : CVI · 2015Article
- Article
- Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant.Human vaccines & immunotherapeutics · 2015Article
- Transcriptional profiling of Neisseria meningitidis interacting with human epithelial cells in a long-term in vitro colonization model.Infection and immunity · 2013Article
- Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?Clinical and vaccine immunology : CVI · 2013Review
- Cross-protective efficacy of recombinant transferrin-binding protein A of Haemophilus parasuis in guinea pigs.Clinical and vaccine immunology : CVI · 2013Article
- Immune response to dna vaccine expressing transferrin binding protein a gene of Pasteurella multocida.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2011Article
- Vaccine development against Neisseria meningitidis.Microbial biotechnology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To better characterize the vaccine potential of Neisseria meningitidis transferrin binding proteins (Tbps), we have overexpressed TbpA and TbpB from Neisseria meningitidis isolate K454 in Escherichia coli. The ability to bind human transferrin was retained by both recombinant proteins, enabling purification by affinity chromotography. The recombinant Tbps were evaluated individually and in combination in a mouse intraperitoneal-infection model to determine their ability to protect against meningococcal infection and to induce cross-reactive and bactericidal antibodies. For the first time, TbpA was found to afford protection against meningococcal challenge when administered as the sole immunogen. In contrast to the protection conferred by TbpB, this protection extended to a serogroup C isolate and strain B16B6, a serogroup B isolate with a lower-molecular-weight TbpB than that from strain K454. However, serum from a TbpB-immunized rabbit was found to be significantly more bactericidal than that from a TbpA-immunized animal. Our evidence demonstrates that TbpA used as a vaccine antigen may provide protection against a wider range of meningococcal strains than does TbpB alone. This protection appears not to be due to complement-mediated lysis and indicates that serum bactericidal activity may not always be the most appropriate predictor of efficacy for protein-based meningococcal vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.